Biotech stocks could be a big opportunity for expo
Post# of 144491
(Total Views: 126)
Posted On: 08/25/2022 7:14:28 AM
Biotech stocks could be a big opportunity for exponential gains
Biotech stocks are always in the spotlight as the sector itself has been the source of significant disruptions for the global healthcare system. Long sought after by both high-risk investors and low-risk investors, biotechnology stocks offer something that other stocks do not: highly speculative opportunities. Because many of these companies are involved in early phase trials of things like novel drugs, a positive result at any phase can end up producing a favorable reaction in the stocks market. And for biotech stock investors, this could be a big opportunity for exponential gains.
Regencell Bioscience, an early-clinical bioscience company which focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases which affects the immune system such as COVID-19.
The company have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. $rgc aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. They are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!
Nasdaq Listing
On July 16, 2021, the ordinary shares began trading on the Nasdaq Capital Market. The company raised net proceeds of approximately $19.3 million from the initial public offering of 2,300,000 ordinary shares at a public offering price of $9.50 per share. They plan to use these proceeds to fund for the second research study (currently ongoing), TCM formulae and products, staff salaries, product and intellectual property registrations, facilities rental, renovations and equipment, for working capital and other general corporate purposes
Biotech stocks are always in the spotlight as the sector itself has been the source of significant disruptions for the global healthcare system. Long sought after by both high-risk investors and low-risk investors, biotechnology stocks offer something that other stocks do not: highly speculative opportunities. Because many of these companies are involved in early phase trials of things like novel drugs, a positive result at any phase can end up producing a favorable reaction in the stocks market. And for biotech stock investors, this could be a big opportunity for exponential gains.
Regencell Bioscience, an early-clinical bioscience company which focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases which affects the immune system such as COVID-19.
The company have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. $rgc aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. They are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!
Nasdaq Listing
On July 16, 2021, the ordinary shares began trading on the Nasdaq Capital Market. The company raised net proceeds of approximately $19.3 million from the initial public offering of 2,300,000 ordinary shares at a public offering price of $9.50 per share. They plan to use these proceeds to fund for the second research study (currently ongoing), TCM formulae and products, staff salaries, product and intellectual property registrations, facilities rental, renovations and equipment, for working capital and other general corporate purposes
(0)
(0)Scroll down for more posts ▼